Market Summary
USD82.53+1.47
Market Closed1.81%
DLB Stock Price
DLB RSI Chart
DLB Valuation
DLB Price/Sales (Trailing)
DLB Profitability
DLB Fundamentals
DLB Revenue
DLB Earnings
Price Action
52 Week Range
61.5588.06
(Low)(High)
Last 7 days
0.8%
Last 30 days
-1.1%
Last 90 days
-0.5%
Trailing 12 Months
6.3%
DLB Financial Health
DLB Investor Care
Peers (Alternatives to Dolby Laboratories)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
APH | 44.9B | 12.6B | -1.30% | 7.70% | 23.44 | 3.55 | 10.43% | 13.56% |
KEYS | 28.8B | 5.6B | 11.94% | 11.13% | 24.94 | 5.19 | 10.78% | 21.45% |
GLW | 26.5B | 13.7B | -6.95% | -12.60% | 28.4 | 1.93 | -5.42% | -50.77% |
ZBRA | 14.9B | 5.8B | -8.66% | -22.36% | 30.01 | 2.57 | 0.74% | -49.88% |
JBL | 11.9B | 35.1B | 12.87% | 45.51% | 12.39 | 0.34 | 14.26% | 19.33% |
| MID-CAP | ||||||||
DLB | 7.9B | 1.3B | -1.09% | 6.33% | 32.65 | 6.19 | 1.65% | 12.47% |
NOVT | 5.9B | 875.8M | 6.30% | 34.68% | 80.67 | 6.77 | 17.02% | 27.07% |
IPGP | 5.2B | 1.4B | -6.33% | 4.72% | 52.01 | 3.71 | -5.29% | -64.10% |
FN | 4.1B | 2.6B | 20.38% | 30.33% | 17.02 | 1.61 | 18.01% | 30.39% |
| SMALL-CAP | ||||||||
OSIS | 2.0B | 1.2B | 0.85% | 41.81% | 23.94 | 1.65 | 2.10% | -22.63% |
KN | 1.6B | 707.6M | 7.60% | -6.45% | -3.62 | 2.32 | -18.53% | -390.64% |
MVIS | 825.6M | 664.0K | 136.87% | 30.28% | -14 | 1.2K | -73.44% | -17.58% |
DGLY | 210.2M | 34.4M | 13.44% | -70.34% | -25.59 | 5.27 | 17.96% | -522.89% |
AIRG | 58.8M | 74.8M | -2.59% | -44.88% | -6.54 | 0.79 | 16.14% | 29.96% |
Financials for Dolby Laboratories
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Revenue | 3.4% | 1,279 | 1,237 | 1,254 | 1,261 | 1,258 |
| Cost Of Revenue | 3.9% | 149 | 143 | 141 | 135 | 131 |
| Gross Profit | 3.3% | 1,130 | 1,094 | 1,112 | 1,126 | 1,127 |
| Operating Expenses | -3.4% | 854 | 884 | 906 | 906 | 897 |
| S&GA Expenses | 3.3% | 355 | 344 | 359 | 367 | 361 |
| R&D Expenses | 0.2% | 257 | 257 | 261 | 261 | 260 |
| EBITDA | 1.4% | 308 | 304 | 322 | 332 | - |
| EBITDA Margin | 2.8% | 0.25* | 0.24* | 0.26* | 0.26* | - |
| Earnings Before Taxes | 33.0% | 298 | 224 | 215 | 227 | 237 |
| EBT Margin | 5.4% | 0.18* | 0.17* | 0.18* | 0.19* | - |
| Interest Expenses | -30.9% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | 32.1% | 242 | 183 | 184 | 201 | 216 |
| Net Income Margin | 1.0% | 0.15* | 0.15* | 0.16* | 0.17* | - |
| Free Cahsflow | 11.8% | 303 | 271 | 328 | 325 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Assets | 3.2% | 2,836 | 2,749 | 2,690 | 2,920 | 3,063 |
| Current Assets | 8.4% | 1,463 | 1,349 | 1,311 | 1,505 | 1,622 |
| Cash Equivalents | 10.7% | 693 | 626 | 620 | 859 | 900 |
| Inventory | 16.2% | 30.00 | 26.00 | 24.00 | 24.00 | 17.00 |
| Net PPE | -0.8% | 508 | 512 | 513 | 518 | 528 |
| Goodwill | 0.2% | 370 | 369 | 365 | 368 | 372 |
| Liabilities | 5.3% | 480 | 456 | 439 | 460 | 458 |
| Current Liabilities | 8.1% | 314 | 290 | 278 | 285 | 281 |
| Shareholder's Equity | 3.0% | 2,356 | 2,288 | 2,246 | 2,454 | 2,605 |
| Retained Earnings | 2.5% | 2,378 | 2,319 | 2,298 | 2,485 | 2,615 |
| Shares Outstanding | -4.3% | 96.00 | 100 | 101 | - | - |
| Minority Interest | 5.3% | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 |
| Cashflow From Operations | 12.1% | 385 | 343 | 319 | 377 | 377 |
| Share Based Compensation | 1.9% | 116 | 114 | 115 | 112 | 109 |
| Cashflow From Investing | 102.1% | 3.00 | -141 | -295 | -270 | -276 |
| Cashflow From Financing | 4.8% | -597 | -627 | -610 | -455 | -302 |
| Dividend Payments | 0.5% | 101 | 101 | 100 | 98.00 | 95.00 |
| Buy Backs | -6.4% | 509 | 544 | 530 | 407 | 256 |
Risks for DLB
What is the probability of a big loss on DLB?
46.1%
Probability that Dolby Laboratories stock will be more than 20% underwater in next one year
25.8%
Probability that Dolby Laboratories stock will be more than 30% underwater in next one year.
0%
Probability that Dolby Laboratories stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does DLB drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Dolby Laboratories was unfortunately bought at previous high price.
Drawdowns
Returns for DLB
Cumulative Returns on DLB
9.9%
10-Year Cumulative Returns
9.0%
7-Year Cumulative Returns
6.5%
5-Year Cumulative Returns
11.5%
3-Year Cumulative Returns
What are the long-term rolling returns for DLB?
FIve years rolling returns for Dolby Laboratories.
Annualized Returns
Which funds bought or sold DLB recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-05-26 | ProShare Advisors LLC | added | 6.19 | 839,110 | 3,773,860 | 0.01% |
2023-05-25 | Empower Advisory Group, LLC | new | - | 740,600 | 740,600 | -% |
2023-05-23 | ROYCE & ASSOCIATES LP | unchanged | - | 995,279 | 5,713,490 | 0.06% |
2023-05-22 | FDx Advisors, Inc. | unchanged | - | - | 1,106,000 | 0.05% |
2023-05-22 | PUTNAM INVESTMENTS LLC | sold off | -100 | -3,321,590 | - | -% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 63.4 | 15,805,000 | 31,954,000 | 0.01% |
2023-05-18 | JPMORGAN CHASE & CO | added | 32.14 | 5,383,470 | 14,350,500 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -0.57 | 4,308,000 | 25,427,000 | 0.03% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -64.7 | -23,688,000 | 17,686,000 | 0.04% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | unchanged | - | 29,106 | 380,916 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Dolby Laboratories News
Schedule 13G FIlings of Dolby Laboratories
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Mar 10, 2023 | vanguard group inc | 10.06% | 6,012,094 | SC 13G/A | |
| Feb 14, 2023 | kayne anderson rudnick investment management llc | 8.54% | 5,110,252 | SC 13G | |
| Feb 10, 2023 | clearbridge investments, llc | 4.8% | 2,903,393 | SC 13G/A | |
| Feb 09, 2023 | morgan stanley | 7.1% | 4,261,695 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 9.94% | 5,963,672 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 5.2% | 3,117,785 | SC 13G | |
| Nov 18, 2022 | dolby dagmar | 37.9% | 308,950 | SC 13D/A | |
| Sep 09, 2022 | vanguard group inc | 10.21% | 6,286,969 | SC 13G/A | |
| Feb 10, 2022 | morgan stanley | 5.9% | 3,849,803 | SC 13G | |
| Feb 09, 2022 | vanguard group inc | 9.48% | 6,157,704 | SC 13G/A |
DLB Fair Value
Recent SEC filings of Dolby Laboratories
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 24, 2023 | SD | SD | |
| May 18, 2023 | 4 | Insider Trading | |
| May 18, 2023 | 4 | Insider Trading | |
| May 16, 2023 | 144 | Notice of Insider Sale Intent | |
| May 16, 2023 | 4 | Insider Trading | |
| May 10, 2023 | 4 | Insider Trading | |
| May 10, 2023 | 4 | Insider Trading | |
| May 08, 2023 | 144 | Notice of Insider Sale Intent | |
| May 08, 2023 | 144 | Notice of Insider Sale Intent | |
| May 05, 2023 | 10-Q | Quarterly Report |
Latest Insider Trading transactions for DLB
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-05-16 | Revankar Shriram | sold (taxes) | -361,311 | 84.32 | -4,285 | svp, advanced technology group |
2023-05-16 | YEAMAN KEVIN J | acquired | 388,109 | 42.98 | 9,030 | president and ceo |
2023-05-16 | YEAMAN KEVIN J | sold | -755,351 | 83.6491 | -9,030 | president and ceo |
2023-05-15 | Couling John D | sold | -23,315 | 83.87 | -278 | svp, entertainment |
2023-05-08 | Rollins Emily | sold | -84,700 | 84.7 | -1,000 | - |
2023-05-08 | SHERMAN MARK ANDREW | acquired | 747,795 | 49.853 | 15,000 | evp, gen. counsel & secretary |
2023-05-08 | SHERMAN MARK ANDREW | sold | -1,253,910 | 83.5943 | -15,000 | evp, gen. counsel & secretary |
2023-04-11 | YEAMAN KEVIN J | sold | -2,598,830 | 84.4352 | -30,779 | president and ceo |
2023-04-11 | YEAMAN KEVIN J | acquired | 1,400,440 | 45.5 | 30,779 | president and ceo |
2023-03-14 | YEAMAN KEVIN J | sold | -2,496,660 | 81.1129 | -30,780 | president and ceo |
Dolby Laboratories, Inc. creates audio and imaging technologies that transform entertainment and communications at the cinema, DTV, transmissions and devices, mobile devices, OTT video and music services, and home entertainment devices. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications.; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, an digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and a range of media devices. Its audio technologies also include Dolby Digital, a digital audio coding technology that provides multichannel sound to applications; Dolby Digital Plus, a digital audio coding technology that offers audio transmission for a range of media applications and devices; Dolby TrueHD, a digital audio coding technology providing encoding for media application; Dolby Vision, an imaging technology for cinema and media devices; Dolby Voice, an audio conferencing technology; and HEVC, a digital video codec with high bandwidth efficiency to support for media devices. In addition, the company designs and manufactures digital cinema servers, cinema processors, amplifiers, loudspeakers, hardware components, video conferencing solutions, and other products for the cinema, television, broadcast, communication, and entertainment industries. Further, it offers various services to support theatrical and television production for cinema exhibition, broadcast, and home entertainment. The company serves film studios, content creators, post-production facilities, cinema operators, broadcasters, and video game designers. It sells its products directly to the end users, as well as through dealers and distributors worldwide. Dolby Laboratories, Inc. was founded in 1965 and is headquartered in San Francisco, California.
DLB Income Statement
2023-03-31Interim Condensed Consolidated Statements Of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2023 | Apr. 01, 2022 | Mar. 31, 2023 | Apr. 01, 2022 | |
| Revenue: | ||||
| Revenue | $ 375,891 | $ 334,371 | $ 710,812 | $ 686,004 |
| Total revenue | 375,891 | 334,371 | 710,812 | 686,004 |
| Cost of revenue: | ||||
| Total cost of revenue | 41,049 | 35,515 | 75,499 | 68,224 |
| Gross profit | 334,842 | 298,856 | 635,313 | 617,780 |
| Operating expenses: | ||||
| Research and development | 67,951 | 67,421 | 132,401 | 136,245 |
| Sales and marketing | 95,695 | 84,230 | 177,900 | 181,400 |
| General and administrative | 61,939 | 98,693 | 121,911 | 161,137 |
| Restructuring charges/(credits) | 33 | 5,162 | (211) | 5,067 |
| Total operating expenses | 225,618 | 255,506 | 432,001 | 483,849 |
| Operating income | 109,224 | 43,350 | 203,312 | 133,931 |
| Other income/(expense): | ||||
| Interest income | 6,773 | 1,098 | 11,651 | 1,814 |
| Interest expense | 34 | (87) | (47) | (171) |
| Other income/(expense), net | 1,250 | (910) | 2,347 | (681) |
| Total other income | 8,057 | 101 | 13,951 | 962 |
| Income before income taxes | 117,281 | 43,451 | 217,263 | 134,893 |
| Provision for income taxes | (21,398) | (6,932) | (41,932) | (18,364) |
| Net income including noncontrolling interest | 95,883 | 36,519 | 175,331 | 116,529 |
| Less: net (income)/loss attributable to noncontrolling interest | (187) | 201 | (260) | 205 |
| Net income attributable to Dolby Laboratories, Inc. | $ 95,696 | $ 36,720 | $ 175,071 | $ 116,734 |
| Net income per share: | ||||
| Basic (in usd per share) | $ 1.00 | $ 0.36 | $ 1.83 | $ 1.15 |
| Diluted (in usd per share) | $ 0.98 | $ 0.36 | $ 1.80 | $ 1.13 |
| Weighted-average shares outstanding: | ||||
| Basic (in shares) | 95,820 | 101,343 | 95,862 | 101,285 |
| Diluted (in shares) | 97,298 | 102,707 | 97,392 | 103,477 |
| Cash dividend declared per common share (in dollars per share) | $ 0.27 | $ 0.25 | $ 0.54 | $ 0.50 |
| Cash dividend paid per common share (in dollars per share) | $ 0.27 | $ 0.25 | $ 0.54 | $ 0.50 |
| Licensing | ||||
| Revenue: | ||||
| Revenue | $ 351,608 | $ 313,833 | $ 659,619 | $ 646,117 |
| Cost of revenue: | ||||
| Cost of revenue | 21,365 | 16,672 | 34,724 | 31,607 |
| Products and services | ||||
| Revenue: | ||||
| Revenue | 24,283 | 20,538 | 51,193 | 39,887 |
| Cost of revenue: | ||||
| Cost of revenue | $ 19,684 | $ 18,843 | $ 40,775 | $ 36,617 |
DLB Balance Sheet
2023-03-31Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2023 | Sep. 30, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 688,443 | $ 620,127 |
| Restricted cash | 4,977 | 8,244 |
| Short-term investments | 126,393 | 189,213 |
| Accounts receivable, net of allowance for credit losses of $9,991 and $11,834 | 283,315 | 243,593 |
| Contract assets, net of allowance for credit losses of $128 and $125 | 275,262 | 176,093 |
| Inventories, net | 30,353 | 23,549 |
| Prepaid expenses and other current assets | 53,853 | 50,075 |
| Total current assets | 1,462,596 | 1,310,894 |
| Long-term investments | 100,797 | 102,514 |
| Property, plant, and equipment, net | 508,021 | 513,481 |
| Operating lease right-of-use assets | 44,721 | 46,530 |
| Intangible assets, net | 98,876 | 112,265 |
| Goodwill | 370,134 | 365,147 |
| Other non-current assets | 47,102 | 55,149 |
| Deferred taxes | 203,886 | 183,568 |
| Total assets | 2,836,133 | 2,689,548 |
| Current liabilities: | ||
| Accounts payable | 17,170 | 14,171 |
| Accrued liabilities | 246,757 | 230,237 |
| Income taxes payable | 14,496 | 1,265 |
| Contract liabilities | 22,963 | 18,588 |
| Operating lease liabilities | 12,625 | 13,257 |
| Total current liabilities | 314,011 | 277,518 |
| Non-current contract liabilities | 22,721 | 23,203 |
| Non-current operating lease liabilities | 35,243 | 37,685 |
| Other non-current liabilities | 108,166 | 100,122 |
| Total liabilities | 480,141 | 438,528 |
| Stockholders’ equity: | ||
| Retained earnings | 2,378,115 | 2,297,730 |
| Accumulated other comprehensive loss | (27,426) | (51,641) |
| Total stockholders’ equity – Dolby Laboratories, Inc. | 2,350,784 | 2,246,183 |
| Noncontrolling interest | 5,208 | 4,837 |
| Total stockholders’ equity | 2,355,992 | 2,251,020 |
| Total liabilities and stockholders’ equity | 2,836,133 | 2,689,548 |
| Class A, $0.001 par value, one vote per share, 500,000,000 shares authorized: 59,671,342 shares issued and outstanding at March 31, 2023 and 59,798,862 at September 30, 2022 | ||
| Stockholders’ equity: | ||
| Common stock | 54 | 53 |
| Class B, $0.001 par value, ten votes per share, 500,000,000 shares authorized: 36,085,779 shares issued and outstanding at March 31, 2023 and 36,085,779 at September 30, 2022 | ||
| Stockholders’ equity: | ||
| Common stock | $ 41 | $ 41 |